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Summary In a prospective study to assess the accuracy of monoclonal immunoscintigraphy for the detection
of axillary lymph node metastases in breast cancer, two murine monoclonal antibodies that react with human
breast cancer (3E1.2 and RCC-1) were labelled with 13'iodine, and the radiolabelled antibody was injected
subcutaneously into the interdigital spaces of both hands of 40 patients, 36 of whom had breast cancer and
the remaining four of whom had fibroadenoma (the normal, contralateral axilla was used as a control). Of
the patients with breast cancer, the findings from the scintigraphy images were correlated with histopathology
or cytology of the axillary lymph nodes; images were regarded as positive and hence indicative of lymph node
metastases if the amount of background-subtracted radioactive count in axilla on the side of breast cancer
exceeded the contralateral normal side by a ratio ) 1.5:1.0 as assessed by computer analysis. Using this
method, immunoscintigraphy had an overall sensitivity of 33% (23% with 1311-3E1.2 and 50% with 1311-
RCC-1) for the detection of lymph node metastases and a specificity of 63% (67% with 1311-3E1.2 and 60%
with 131I-RCC-1) with problems of non-specific uptake by presumably normal lymph nodes. The results of
immunoscintigraphy obtained with 1311-RCC-1 (IgG) were superior to 1311-3E1.2 (IgM) although the
accuracy of immunoscintigraphy using 131I-RCC-1 (56%) was not much better than preoperative clinical
assessment (50%). However, there were cases when immunoscintigraphy using radiolabelled antibody (IgM or
IgG) detected axillary lymph node metastases not suspected by clinical examination. Thus it appears that
while immunoscintigraphy may be a useful adjunct to preoperative clinical assessment and is simple and safe,
a major improvement in its accuracy is needed before it can replace axillary dissection and histological
examination in the accurate staging of axilla in breast cancer.
The detection of overt tumour deposits by means of gamma-
camera imaging and radiolabelled monoclonal antibodies to
tumour-associated antigens (immunoscintigraphy) has met
with encouraging results (Armitage et al., 1984; Epenetos,
1985; Leyden et al., 1986; Mach et al., 1981; Rainsbury,
1984; Smedley et al., 1983; William et al., 1984). However,
most of these studies have been performed on patients with
well documented and widespread disease; few being prospec-
tive studies of the value of monoclonal immunoscintigraphy
in the initial staging of patients with malignant disease.
Immunoscintigraphy is complicated in that imaging using
intravenously administered radiolabelled antibodies has a
considerable background radioactivity because of the uptake
of radiolabelled material in the blood pool and extravascular
spaces, and antibodies may be catabolised before reaching
their target, resulting in only a very small tumour uptake. In
addition, dehalogenation of radiolabelled antibody, poor
penetration of the conjugate into tumour deposits and
antibody binding to cross-reactive antigens present on
normal cells are further limitations to successful antibody
targetting and therefore of immunoscintigraphy (Bradwell et
al., 1985; Rockoff et al., 1980).
It is possible that intra-lymphatic delivery of antibody may
avoid some of these problems. Several investigators have
used subcutaneously injected radiolabelled anti-tumour anti-
bodies to delineate metastatic deposits in regional lymph
nodes (DeLand et al., 1979; Thompson et al., 1984) follow-
ing the demonstration, in animals, that this route of admi-
nistration permits more efficient delivery (>20% of injected
dose) to lymphoid target cells in regional lymph nodes and
avoids background uptake in other sites (Weinstein et al.
1982, 1984). It is suggested that this high level of antibody
uptake into tumour-containing lymph nodes was due to the
presence of an intact basement membrane about blood
vessels, and the absence of one about lymphatics, allowing
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the preferential uptake to the lymphatics (Bergvist et al.,
1983; Leak, 1971; Weinstein et al., 1983, 1984). Thompson et
al. (1984) reported a preliminary study of eight patients with
breast cancer uising subcutaneously administered 131I-labelled
anti-breast cancer antibody (3E1.2) and showed accurate
localisation of tumour deposits in axillary lymph nodes in
seven axillae with palpable lymph nodes and in two axillae
with impalpable lymph nodes. On this basis, a prospective
study in a larger number of patients presenting with sus-
pected breast cancer was performed using the same
techniques.
Materials and methods
Monoclonal antibodies
The murine monoclonal anti-breast antibodies (MoAbs) used
were 3E1.2 (IgM) and RCC-1 (IgG 2a, formerly called 17.1),
(Stacker et al., 1985; Thompson et al., 1983). By immuno-
peroxidase staining both 3E1.2 and RCC-1 antibodies react
strongly with the membrane and cytoplasm of breast carci-
nomas in about 90% of cases and have only minimal
reaction with normal breast tissue and with the tissues of
relevance to this study (e.g. muscle, fat, endothelium, lymph
nodes or erythrocytes). The monoclonal antibody 3E1.2 was
raised against fresh human breast carcinoma (Stacker et al.,
1985) and was obtained in the ascites form. Purification of
the 3E1.2 antibody from ascites fluid was achieved by
treatment with Freon (CICF2,CCI2F; Aldrich Chemical Co.,
Milwaukee, WI) to remove lipid, then dialysis against 5mM
Tris-HCl pH 7.5 and the precipitate was resuspended in
20mM borate buffer pH 8.0, 0.3 M NaCl. The monoclonal
antibody RCC-1 was produced by immunising inbred Biozzi
mice with the MCF-7 breast cell line (Thompson et al., 1983)
and was isolated from ascitic fluid by precipitation with 40%
ammonium sulphate, then purified by adsorption onto
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Protein A-Sepharose (Pharmacia Inc., Piscataway, NJ) and
eluting with 0.2M glycine-HCl (pH2.8).
The antibody activity was determined either by a rosetting
technique (Parish & McKenzie, 1978) or by the immuno-
peroxidase method on sections of breast carcinoma and the
purity tested by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE). The purified antibodies were
filtered through a 0.22,um Millex-GV filter (Millipore, Bed-
ford, Ann Arbor, MI) and tested for pyrogens and sterility
before and after radiolabelling (Pharmacology Department,
Melbourne University and Sigma Pharmaceuticals, Clayton,
Victoria, Australia).
Iodination of monoclonal antibodies
On the day of injection, purified 3E1.2 antibody or RCC-1
antibody (50-200pg) was labelled with 5mCi of 131I to a
specific activity of 1-5mCi of 131I per mg of antibody by
means of iodobead (Markwell, 1982) or chloramine T
method (Greenwood et al., 1963) and the 311-labelled
antibody was separated from free iodine on a Sephadex G-25
column (PD10, Pharmacia, Sweden). The radioactivity of the
iodinated antibody was measured in both a gamma counter
(LKB Wallac 1260, Finland) and a radioisotope dose cali-
brator (Capintec CRC-2Ni, Capintec, New York) and the
radiolabelled protein peak pooled. The sample was centri-
fuged at 100,000g for 60min to remove aggregated proteins
and filtered through a 0.22pm Millipore filter in a sterile
laminar-flow hood. The immunoreactivity of the antibody
was tested before and after radioiodination by rosetting
techniques or by the immunoperoxidase staining as described
above.
Patients
Forty patients with clinically suspected breast cancer were
studied prospectively. Following histological or cytological
examination, 36/40 patients had breast cancer (33 had stage
I or II and three had stage IV breast cancer using the
standard UICC classification) and 4/40 patients had benign
breast disease (Bearhs & Myers, 1983). The radiolabelled
antibody was injected subcutaneously in the inter-digital
spaces of both hands; each patient also received potassium
iodide (2ml at 16.54% w/v) and sodium perchlorate (400mg)
orally 1 h before the injection to inhibit thyroid uptake of
1311; the potassium iodide was continued for 6 days after the
injection. Of the patients studied, 55% (22/40) received 1311-
3E1.2 antibody and the remainder 1311-RCC-1 antibody.
Blood samples were obtained from 24/40 patients immedia-
tely before and 4 weeks after injection of radioiodinated
monoclonal antibody for determining human anti-mouse
antibody (HAMA) response. The clinical data were not
made available until completion of the study.
Imaging
About 16-24h after injection of the radiolabelled antibody,
anterior scintiphotos of chest and both axillae were obtained
with a Toshiba GCA402 gamma-camera using a high-energy
parallel hole collimator and computerised acquisition with an
Informatek Simis 4 computer. A window setting of 360keV
with a 20% window was used, images were obtained over a
period of 600 seconds and then digitally recorded into a
matrix of 128 x 128 words. Regions of interest in the images
were defined by manual drawing by two independent
observers over the axillary lymph node regions on both sides
using anatomical landmarks as well as adjacent background
and has been found to be remarkably reproducible. The data
were decay-corrected and the fraction of radiolabelled anti-
body localised in the axillary nodes (F) was estimated by
measurement of nodal uptake (N) with the gamma-camera,
and compared with uptake in the other regions of interest
and the amount of radiolabelled antibody injected (1). Nodal
uptake was adjusted for background activity (b), camera
response and attenuation through the anterior axillary fold
using an attenuation factor (A) calculated using a known
source placed in the axilla. The following formulae were
used:
F(%)=N1/Ix 100 [1]
N2(c.p.m.)=N1(pCi) xcamera sensitivity
E (PPb] eA
[2]
[3]
where F=fraction of radiolabelled antibody localised in the
nodes; N=nodal uptake (N1 in pCi, N2 in c.p.m.); n=total
gamma camera counts (c.p.m.) over lymph node regions;
I=actual injected dose (pCi); b=background activity
(c.p.m.); Pn=number of pixels in region of interest (lymph
node region); Pb=number of pixels in background; A=
attenuation factor; e-" =factor for isotope decay=0.94 for
13"I at 18h; camera sensitivity (122.4c.p.m. pCi-') was
determined by counting the amount of count per minute
(c.p.m.) with known amount (1 Ci) of 131i.
Studies were reported as positive and therefore indicative
of lymph node metastases if the number of counts in the
axilla on the tumour side exceeded the normal side by a
ratio equal to or greater than 1.5:1.0, after adjustment for
background activity as indicated above. The amount of
nodal uptake of radioactivity in pCi (N1) was also calculated
for each axilla using the above formulae and the mean nodal
uptake in each axilla was expressed as the percentage (%) of
the injected dose. A comparison of the mean nodal uptake
between axillae with and without lymph node metastases can
therefore be made.
Analysis of excised axillary lymph nodes
Each node was processed and 6pm sections were stained
with Haematoxylin and Eosin for histological examination.
Immunoperoxidase staining was performed in some cases of
snap-frozen sections (with RCC-1 antibody) or formalin
fixed, paraffin embedded sections (with 3E1.2 antibody)
(Thompson et al., 1983; Tjandra et al., 1988).
Human anti-mouse antibody response
Human antibodies against the murine MoAbs were mea-
sured by an enzyme linked immunosorbent assay (ELISA),
modified from that previously described (Schroff et al.,
1985). Ninety-six-well flexible polyvinyl chloride plates (Cos-
tar, Cambridge, MA) were coated with 50pl per well of
administered MoAb (5ugml-1 of purified 3E1.2 or RCC-1
MoAbs) in a 0.1 M carbonate buffer, pH 9.6 and incubated at
37°C for 2h. The plates were then washed with PBS, 0.05%
Tween and non-specific binding blocked with 1% bovine
serum albumin, PBS pH7.6 for 2h at 37°C. Serial dilution
of patients' sera and pooled normal human serum (50p1 per
well) in PBS, 0.05% Tween 20 were performed. After
washing the coated and blocked plate with PBS, 0.05%
Tween 20, diluted serum samples (50l1 per well) were added
to the coated wells and left for overnight incubation at 4°C.
Plates were then washed with PBS, 0.05% Tween 20 and
then reacted with 50pl per well of phosphatase-labelled
affinity purified goat anti-human immunoglobulin
(Kirkegaard and Parry, MD) at 37°C for 3 h. The plates
were then washed extensively with PBS, 0.05% Tween 20
and 50p1 per well of alkaline phosphatase substrate was
added. The colour reaction was read with an ELISA plate
reader (Titretek, Multiscan, MC) at a wavelength of 405nm.
Results were expressed as the absorbance value of patient
serum compared with pooled normal human serum and a
positive test was considered to be a value at least twice the
control.298 J.J. TJANDRA et al.
Statistical analysis
The data were analysed statistically using the x2 test and
P<0.05 was regarded as significant.
Results
The investigations were performed essentially as outpatient
procedures unless for special medical or social reasons
relevant to the surgery when the patients were in hospital.
Toxicity
Antibody administration was well tolerated by all the
patients with no adverse reactions occurring except for the
development of human anti-mouse antibody response at 4
weeks after injection in 2/24 patients (patients 1 and 32), one
of whom had 1311-3E1.2 and the other 131I-RCC-l.
Immunoscintigraphy with 131I-3EL.2 (IgM)
The results of the scans in 22 patients (patients 1-22) with
suspected primary breast cancer are shown in Table I. These
were correlated with histological or cytological examination
of the axillary lymph nodes except in patients subsequently
proved to have benign breast disease. Correct prediction of
the axillary lymph node status was obtained in 41% (9/22)
of the patients by the preoperative scans and in 59% (13/22)
of the patients by preoperative clinical assessment (Table II).
Thirteen of the 22 patients had histologically or cytologically
proven axillary lymph node metastases: 3/13 (23%) patients
were detected by the scan, and 7/13 (54%) patients by
clinical examination. Nine of the 22 patients did not have
lymph node metastases and a negative scan was obtained in
6/9 (67%) patients; in a comparable number (6/9 or 67%),
the axillae were considered not involved by metastases on
clinical examination (Table I).
Table I Clinical, histology and immunoscintigraphy data in patients with suspected breast cancer
Histologya
Ductal
Ductal stage IV
Fibroadenoma
Ductal
Ductal stage IV
Ductal
Ductal
Ductal
Ductal
Ductal
Ductal
Ductal
Ductal
Ductal
Ductal
Ductal
Neuro-endocrine
Lobular
Ductal
Mixed ductal and lobular
Ductal
Ductal
Axillaryb
nodal pathology
0/18
+
0/11
+
1/20
2/18
4/26
0/6
6/12
5/11
0/19
5/9
5/18
4/10
0/14
0
0/8
1/13
3/12
0/10
4/16
Clinical nodal Scanc
involvement ratio
No
Yes
No
Yes
Yes
No
Yes
No
Yes
No
Yes
No
No
Yes
Yes
No
No
No
No
No
Yes
Yes
1.0:1.0
2.0:1.0
1.0:1.0
1.0:1.0
1.0:1.0
1.0:1.0
1.0:1.0
1.0:1.0
1.0:1.0
3.0:1.0
1.0:1.0
1.8:1.0
1.0:1.0
1.2:1.0
1.0:1.0
1.8:1.0
1.4:1.0
<1.0:1.0
1.0:1.0
1.5:1.0
2.6:1.0
1.0:1.0
Scand
result
TN
TP
TN
TN
FN
FN
FN
FN
TN
TP
FN
FP
FN
FN
FN
FP
TN
TN
FN
TP
FP
FN
13II-RCC-1
23 Left Fibroadenoma Yes 1.0:1.0 TN
24 Right Ductal 0/12 Yes 1.0:1.0 TN
25 Left Ductal 1/14 No 2.0:1.0 TP
26 Right Ductal 2/22 No 1.0:1.0 FN
27 Right Ductal 0/15 Yes 1.5:1.0 FP
28 Left Lobular 2/3 No 2.2:1.0 TP
29 Right Carcinoma in situ 0/13 No 1.0:1.0 TN
30 Right Ductal 3/13 No <1.0:1.0 FN
31 Left Ductal stage IV + Yes 1.1:1.0 FN
32 Left Ductal 14/21 Yes 3.0:1.0 TP
33 Left Fibroadenoma - No 1.9:1.0 FP
34 Right Ductal 0/16 No 1.4:1.0 TN
35 Right Lobular 14/22 Yes 2.7:1.0 TP
36 Right Ductal 0/14 No 1.2:1.0 TN
37 Right Lobular 0 Yes < 1.0: 1.0 TN
38 Right Fibroadenoma - No 2.0:1.0 FP
39 Left Ductal 4/8 Yes 1.0:1.0 FN
40 Right Ductal 0/14 Yes 2.0:1.0 FP
aAll patients had breast carcinoma, except patients 3, 23, 33 and 38, who had fibroadenoma, and patient 17, who had malignant
neuroendocrine tumour; bNodal metastases expressed as the number of involved nodes/total number of nodes recovered from axillary
dissection specimen; 0 indicates no nodal metastases but the total number of lymph nodes examined not specified; + indicates nodal metastases
as assessed by clinical examination and fine needle aspiration cytology in patients with stage IV breast cancer; - indicates that axillary
dissection was not performed; CScan ratio expressed as the ratio of background-subtracted radioactive count of the axilla ipsilateral to breast
tumour to that of contralateral axilla. A ratio > 1.5:1.0 was regarded as indicative of lymph node metastases; dTP, true positive; FP, false
positive; TN, true negative; FN, false negative.
Patient
131I-3EL2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Side of
tumour
Left
Right
Right
Right
Right
Left
Right
Left
Right
Right
Left
Left
Right
Right
Left
Left
Left
Right
Right
Right
Right
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Table II Comparison of immunoscintigraphy with clinical and pathological assessment of the axillae in
patients with suspected breast cancer
Pathological' Immunoscintigraphyb Clinical assessmentc Immunoscintigraphy +ve
assessment +ve +ve and/or clinical +ve
131I-3EL2
Node +ve 3/13 (23%) 7/13 (54%) 9/13 (69%)
Node -ve 3/9 (33%) 3/9 (33%) 5/9 (56%)
'31I-RCC-1
Node +ve 4/8 (50%) 4/8 (50%) 6/8 (75%)
Node -ve 4/10 (40%) 5/10 (50%) 7/10 (70%)
aNode +ve implies > 1 nodal metastases; node -ve implies no nodal metastases, as confirmed by
histological or cytological examination; "+ve implies scan ratio of axilla of interest to contralateral axilla of
> 1.5: 1.0, which indicates the presence of lymph node metastases; c+ve implies palpable axillary lymph nodes
felt to contain tumour deposits on clinical assessment.
Immunoscintigraphy with I31I-RCC-1 (IgG 2a)
Patients 23-40 in Table I received 131I-RCC-l and correct
prediction of the axillary lymph node status by the scan was
obtained in 56% (10/18) of the patients, comparable with
preoperative clinical assessment (50% or 9/18) (Table II).
Eight of the patients had histologically proven axillary
lymph node metastases: 4/8 (50%) patients were detected by
the scan and 4/8 (50%) patients by clinical examination. Ten
of the 18 patients did not have lymph node metastases: a
negative scan was obtained in 6/10 (60%) of the patients,
and in 5/10 (50%) patients the axillae were considered not
involved by metastases on clinical examination (Table I).
Illustrative cases
Some examples of representative scintigraphy images are
described in more detail below.
Patient 9 was considered to have involved axillary lymph
nodes on clinical assessment but the scintigraphy images
showed equal uptake of 1311-3E1.2 in both axillae with a
ratio of background subtracted count of 1.0:1.0 between the
two axillae (Figure 1). Histology of the six lymph nodes
recovered showed reactive hyperplasia with no metastases.
Patient 10 was considered not to have involved axillary
lymph nodes clinically but immunoscintigraphy with 1311-
3E1.2 showed preferential uptake of radioactivity in the right
axilla (ipsilateral to the side of breast cancer) with a scan
ratio of 3.0:1.0 between right and left axillae (Figure 2).
Subsequent histology of the axillary dissection specimen
showed the presence of metastases in 6/12 lymph nodes.
Patient 32 with left sided breast cancer was considered to
have axillary lymph node involvement clinically and to have
scintigraphy images suggestive of lymph node metastases
(scan ratio of left axilla to right axilla=3.0:1.0); histology
confirmed the presence of metastases in 14/21 lymph nodes
(Figure 3).
Despite many scintigraphy images showing good preferen-
tial localisation in axillae with lymph node metastases, non-
specific uptake of radiolabelled antibody in contralateral
normal axilla by presumably normal lymph nodes was a
major problem, making interpretation of the scintigraphy
images difficult (Figure 4). This 'non-specific' uptake
appeared to be more prominent with IgM antibody (3E1.2).
Biodistribution data
In 40 patients the fraction of monoclonal antibody retained
in the nodes (F), calculated as a percentage of the actual
injected dose, was determined using formulae 1, 2 and 3
based on the gamma-camera count rates. These results are
summarised in Table III and show that node positive axillae
appeared to have a higher mean nodal uptake of radio-
labelled RCC-1 (IgG) than those with negative nodes
(1.3:1.0), although there was some overlap between the
positive and negative axillae; however, such differences were
not apparent with 1311-3E1.2 (IgM).
Figure 1 Scintigraphic image of the anterior chest including
both axillae in a patient with right breast cancer and palpably
enlarged right axillary lymph nodes - none of the lymph nodes
contained tumour deposits on histology. The respective regions
of interest were as follows: A, right axilla; B, background region
adjacent to right axillary region; C, left axilla and D, back-
ground region adjacent to left axillary region. Scan ratio of right
to left=L.0:1.0.
Figure 2 Scintigraphic image showing an increased uptake of
radiolabelled antibody in right axilla (scan ratio of right to
left=2.0: 1.0) which corresponded to the presence of lymph node
metastases.300 J.J. TJANDRA et al.
Figure 3 Scintigraphic image of anterior chest in a patient with
left breast cancer and left axillary lymph node metastases. Scan
ratio of left to right =3.0:1.0.
Figure 4 Scintigraphic image in a patient who received 1311-
3E1.2. There was equally significant uptake of radioactivity in
both right (R) and left (L) axillae (scan ratio = 1.0:1.0) although
the patient had breast cancer and histologically proven lymph
node metastases on the right side only. The uptake of radio-
activity by thyroid (T) was noted despite prophylactic thyroid
suppression with potassium iodide and sodium perchlorate.
Table III Nodal uptake (%) of 1311-3E1.2 or 13lI-RCC-
1 in axillae with and without lymph node metastases
Mean nodal uptake (±s.d.)
as % of injected doseb
Pathologya l3lI-3E1.2 13lI-RCC-1
Positive axilla 4.8+1.6% 5.6+2.0%
Negative axilla 4.4+ 1.0% 4.3+0.8%
aPositive axilla implies > 1 lymph node metastases;
negative implies there was no lymph node metastases, as
assessed by histological or cytological examination; bMean
nodal uptake as calculated using formulae 1, 2 and 3 in
the text; s.d.=standard deviation.
Discussion
Currently the best prognostic factor in breast cancer, in the
absence of distant dissemination, is the involvement of
ipsilateral axillary lymph nodes. This is also the main
indicator for the need for adjuvant therapy. As the clinical
assessment of axillae is unreliable, the accurate detection of
axillary lymph node metastases will usually require axillary
dissection, a procedure which has an associated morbidity.
The use of radiolabelled antibodies for the detection of
lymph node metastases is therefore an attractive concept
which, if sufficiently sensitive and specific, may replace
surgical axillary dissection. However, despite recent reports
on immunoscintigraphy (Epenetos, 1985; Thompson et al.,
1984), there are few prospective studies of immunoscinti-
graphy for the detection of axillary lymph node metastases
and to relate findings from the scintigraphy with histology of
the lymph nodes.
We now report a study of immunoscintigraphy in 40
patients. An important feature was the quantitative analysis
of the scintigraphy images by obtaining a ratio of back-
ground-subtracted radioactive count of either axilla. This
added objectivity to the interpretation of the scintigraphy
images, compared to the conventional visual interpretation.
It was found that a ratio > 1.5:1.0 between the axilla of
interest and the normal axilla was significant and this was
selected because at and above that ratio there was an
obvious visual difference between the scintigraphy images of
the axillae and, furthermore, it gave optimal accuracy in the
detection of lymph node metastases in the study.
This study shows that immunoscintigraphy can localise
lymph node metastases in a proportion of patients with
breast cancer. The overall sensitivity in the detection of
lymph node metastases was 33% (7/21) by immunoscinti-
graphy (23% with 1311-3EI.2 and 50% with 131I-RCC-1)
and 52% (11/21) by clinical examination; the overall specifi-
city was 63% by immunoscintigraphy (67% with 1311-3E1.2
and 60% with 1311-RCC-1) and 58% by clinical examin-
ation. While the specificity of immunoscintigraphy with 31I-
3E1.2 was comparable with 1311-RCC-1 (P=0.5), there was
an improvement in sensitivity in the detection of lymph node
metastases with IgG (RCC-1) antibody when compared with
IgM (3E1.2) antibody, although the differences in sensitivity
were not statistically significant, mainly because of the small
number of patients studied (P=0.2) (Table II). In addition,
there were cases when immunoscintigraphy detected axillary
lymph node metastases not suspected by clinical examin-
ation. The overall accuracy of immunoscintigraphy using
1311-RCC-1 (56% or 10/18) was not much superior to
preoperative clinical assessment (50% or 9/18). If both
modalities of assessment (clinical assessment and immuno-
scintigraphy) were combined, in that either abnormal finding
was regarded as significant, there was an improvement in
sensitivity in the detection of lymph node metastases but
with a concomitant deterioration in the specificity (Table II).
The presence of tumour-associated antigens recognised by
monoclonal antibodies 3E1.2 and RCC-1 was demonstrated
in the lymph node of some patients by immunoperoxidase
staining (data not shown) and high nodal uptake of radioac-
tivity in some axillae with lymph node metastases compared
with normal axillae was noted (patients 10 and 32). How-
ever, the concentration of radiolabelled antibody in the
axillae, calculated using formulae 1, 2 and 3, indicated that
when 131I-RCC-1 was used, the fraction of injected dose
accumulated in the axillae with involved nodes (- 5.6%) was
only slightly higher than in those with uninvolved nodes
(-4.3%) although there was some overlap between the
positive and negative axillae. There was no difference when
1311-3EI.2 was administered (4.8% vs. 4.4%). The correla-
tion of the uptake of radiolabelled antibody by involved
lymph nodes with their antigen content as assessed by
immunoperoxidase staining would be of interest but was not
performed in each case because of the practical difficulty of
obtaining and identifying fresh lymph nodes in each case
(RCC-1 antibody only reacts with fresh tissue sections).
A major problem identified was the non-specific uptake of
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when IgM antibody was administered. This made inter-
pretation of the scintigraphic image difficult, even with the
quantitative analysis to obtain a ratio of background-
subtracted radioactive count between the axilla of interest
and the normal contralateral axilla. Thus, the presence of
reactive lymph nodes in the axilla, on the side of breast
cancer, can lead to the uptake of radiolabelled antibody
leading to false positive scintigraphic images, while the non-
specific uptake of radioactive material in the normal contra-
lateral axilla could also lead to false negative interpretation
of scintigraphic images. This phenomenon has also been
described by other investigators (Epenetos, 1985; Nelp et al.,
1987). It is likely that this may be due, in part, to binding
through the Fc portion of the mouse immunoglobulin. The
large size of the IgM antibody probably caused significantly
more non-specific binding than the smaller IgG antibody.
However, when radiolabelled F(ab')2 fragments of RCC-1
antibody were used for immunoscintigraphy, there was
equally significant non-specific uptake of radiolabelled anti-
body fragment by normal axilla (data not shown). Further
larger studies with antibody fragments to avoid Fc binding
or with other measures which may saturate non-specific
binding sites of normal lymph nodes, such as the addition to
radiolabelled antibody of excess irrelevant antibody of the
same Ig isotype, are currently in progress.
Although the results of immunoscintigraphy in this study
are of interest, and indicate that it may be a useful adjunct
to preoperative clinical assessment, a major improvement in
its accuracy is needed before axillary dissection and histo-
logical examination can be replaced as the standard method
of staging axilla in breast cancer. However, immunoscinti-
graphy is simple and safe, and it is more specific than colloid
lymphoscintigraphy (Gasparini et al., 1987), a technique in
which radiolabelled particles are injected subcutaneously and
are taken up by macrophages in the draining lymph nodes.
Subcutaneous immunoscintigraphy is also more efficient
than the intravenous route of immunoscintigraphy when the
aim is to deliver radiolabelled antibody to regional lymph
nodes (Bunn et al., 1984; Keenan et al., 1987). The results of
this prospective study fell short of the previous results
(Thompson et al., 1984) and indicated that the one IgG
antibody used was preferable to an IgM antibody, but
whether this holds true for other antibodies remains to be
seen. However, the major problem identified is the so-called
'non-specific' uptake of mouse immunoglobulin by the drain-
ing lymph nodes. However, while this is an annoying
problem in immunoscintigraphy, we suspect greater clinical
problems would result if the lymph nodes were not able to
remove up to 1 mg of foreign protein, i.e. the 'non-specific'
uptake is normal. How this is to be overcome is now a
major problem in immunoscintigraphy, particularly when
examining the regional lymph nodes. This study clearly
demonstrates that antibodies for tumour imaging must be
assessed prospectively in large clinical studies and that
monoclonal antibodies of the IgM class are not optimal for
radioimmunolocalisation by lymphoscintigraphy.
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